AstraZeneca India Q1 FY27 Results: Revenue Rs 682 Cr, PAT Rs 37 Cr and Key Highlights
- August 11, 2026
- Posted by: Lakshit Sharma
- Category: News
AstraZeneca India Q1 FY27 results declared August 10, 2026. Revenue Rs 682 Cr (+29.73% YoY). PAT Rs 37 Cr (-32.06% YoY). CMP Rs 8090.0 (-1.23%).
AstraZeneca India Q1 FY27 results were declared on August 10, 2026 on a standalone basis. Revenue expanded +29.73% YoY to Rs 682 Cr from Rs 526 Cr in Q1 FY26. The broader Nifty Pharma index reflected mixed sentiment during the quarter.
Operating profit stood at Rs 43 Cr (-32.27% YoY). PAT came in at Rs 37 Cr (-32.06% YoY), reflecting the key financial metrics of AstraZeneca India Q1 FY27 results.
Click Here – Get Free Investment Predictions
AstraZeneca India Q1 FY27 Financial Highlights
| Metric | Q1 FY27 (Rs Cr) | Q1 FY26 (Rs Cr) | YoY Change |
|---|---|---|---|
| AstraZeneca India Revenue | 682 | 526 | +29.73% |
| Operating Profit | 43 | 64 | -32.27% |
| Net Profit (PAT) | 37 | 55 | -32.06% |
| Reporting Basis | Standalone | ||
AstraZeneca India Q1 FY27 Performance Analysis
Check the Univest Screener for Live Data on This Stock
AstraZeneca India Q1 FY27 results reflect under-pressure fundamentals. Revenue momentum were evident with the top line reaching Rs 682 Cr for the April to June 2026 quarter.
Operating profit contracted -32.27% YoY. PAT of Rs 37 Cr reflects -32.06% YoY movement. Investors tracking AstraZeneca India Q1 FY27 results will note these as key FY27 milestones.
Key Business Factors in AstraZeneca India Q1 FY27 Results
Revenue Expansion in Q1 FY27
AstraZeneca India Q1 FY27 results show revenue expanding +29.73% YoY to Rs 682 Cr from Rs 526 Cr in Q1 FY26. Volume-led growth and market share gains in the Pharmaceuticals segment drove the uptick.
Margin Pressure from Cost Headwinds
Operating profit in AstraZeneca India Q1 FY27 results stood at Rs 43 Cr (-32.27% YoY). Input cost inflation and competitive dynamics weighed on operating profitability.
PAT Trajectory and Profitability
PAT in AstraZeneca India Q1 FY27 results was Rs 37 Cr (-32.06% YoY), reflecting near-term operational challenges.
Dividend Details
No dividend was declared alongside AstraZeneca India Q1 FY27 results. Earnings are being channelled toward operational reinvestment and working capital.
FY27 Outlook for AstraZeneca India
Following AstraZeneca India Q1 FY27 results, management has focused on a recovery-driven strategy centred on cost reduction, revenue diversification, and return to profitability in the pharmaceuticals segment. Investors tracking AstraZeneca India Q1 FY27 results should consult a SEBI-registered financial advisor.
AstraZeneca India Stock Performance After Q1 FY27 Results
Download the Univest iOS App or Univest Android App to track AstraZeneca India live price and get daily stock recommendations.
AstraZeneca India shares were trading lower at Rs 8090.0 (-1.23%) on August 10, 2026, reflecting investor sentiment on AstraZeneca India Q1 FY27 results and the near-term sector outlook. The CMP of Rs 8090.0 on the results date reflects broader sentiment toward the pharmaceuticals space.
Key Risks for AstraZeneca India
Sector-Specific Risks
USFDA regulatory actions, generic pricing pressure, and API cost inflation remain core risks.
Valuation and Earnings Risk
Sustained margin compression and limited near-term earnings visibility may delay re-rating.
Operational and Financial Risk
Working capital intensity and cash conversion cycle elongation could strain standalone cash flows.
Conclusion
AstraZeneca India Q1 FY27 results reflect under-pressure performance with revenue at Rs 682 Cr and PAT at Rs 37 Cr on a Standalone basis. Sector tailwinds and operational discipline will shape the FY27 trajectory. Investors should review management commentary before taking any position.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on AstraZeneca India Q1 FY27 Results
When were AstraZeneca India Q1 FY27 results declared?
Ans. AstraZeneca India Q1 FY27 results were declared on August 10, 2026, covering the April–June 2026 quarter on a Standalone basis.
What was AstraZeneca India revenue in Q1 FY27?
Ans. Revenue in AstraZeneca India Q1 FY27 results was Rs 682 Cr, +29.73% YoY from Rs 526 Cr in Q1 FY26.
What was AstraZeneca India PAT in Q1 FY27?
Ans. Net profit in AstraZeneca India Q1 FY27 results was Rs 37 Cr (-32.06% YoY).
Did AstraZeneca India declare a dividend in Q1 FY27?
Ans. No dividend was announced alongside AstraZeneca India Q1 FY27 results. Refer to official NSE and BSE announcements for future dividend updates.
What is the FY27 outlook for AstraZeneca India?
Ans. Management has guided operational restructuring and return to profitability for FY27. Sector demand and execution will be key monitorables.
How did AstraZeneca India stock react to Q1 FY27 results?
Ans. AstraZeneca India shares were lower at Rs 8090.0 (-1.23%) on August 10, 2026. Consult a SEBI-registered financial advisor before acting on price movements.